J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen

Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher. The chief executives of Johnson & Johnson JNJ, -0.96%, Merck & Co. MRK, -0.63% and Bristol Myers Squibb Co. BMY, -0.05% were faced with sharp questioning from Sen. Bernie Sanders, the Vermont independent, and other members of the Senate Health, Education, Labor and Pensions Committee demanding to know why U.S. p ...